DEF: Moderna's 2025 Proxy Statement: Board Elections, Executive Pay, and Auditor Ratification on the Agenda

Moderna's 2025 proxy statement outlines key proposals for the annual shareholder meeting, including the election of directors, an advisory vote on executive compensation, and the ratification of the company's independent auditor.

Summary

• Moderna's annual meeting of shareholders will be held virtually on April 30, 2025.
• Shareholders will vote on the election of three Class I directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor.
• The Board of Directors recommends voting FOR all director nominees, the executive compensation proposal, and the auditor ratification.
• Moderna reported $3.1 billion in net product sales for 2024 and has $9.5 billion in cash, cash equivalents, and investments as of December 31, 2024.
• The company aims to secure up to 10 product approvals over the next three years and reduce annual R&D expenses by approximately $1 billion by 2027 compared to 2024.
• The Board has implemented governance enhancements, including majority voting for uncontested director elections, a proxy access bylaw, and a special meeting right for shareholders.
• Executive compensation is based on a pay-for-performance philosophy, with a significant portion of compensation tied to company performance goals.
• The corporate performance scorecard for 2024 resulted in a funding outcome at 102% of target.
• The 2022-2024 PSU program resulted in a 55% payout.
• Special equity awards were granted to the Chief Financial Officer and Chief Legal Officer to address the gap between target and realizable equity value and to strengthen retention.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While highlighting positive advancements in the pipeline and cost efficiencies, it acknowledges challenges in commercial execution and a decline in the stock price. The overall tone is cautiously optimistic.

Positives

• Moderna achieved $3.1 billion in net product sales in 2024.
• The company has $9.5 billion in cash, cash equivalents, and investments.
• Moderna is targeting up to 10 product approvals over the next three years.
• The company plans to reduce annual R&D expenses by approximately $1 billion by 2027 compared to 2024.
• The Board has implemented governance enhancements, including majority voting for uncontested director elections, a proxy access bylaw, and a special meeting right for shareholders.
• The company has 11 late-stage programs and a total of 44 programs in development.
• The company reduced cash operating costs by 27% in 2024 compared to 2023.

Negatives

• Product sales fell short of internal targets.
• The U.S. RSV market in 2024 was marked by significant competition.
• The company had to prioritize development programs to focus on those with the greatest likelihood of approval and revenue generation.
• The company's stock price has faced significant pressure over the past three years.

Risks

• Expected product launches are subject to clinical trial, regulatory, and commercial success, and availability of supply.
• The company faces increased competition and a decline in vaccination rates in the COVID vaccines market.
• The company's ability to deliver consistent revenue growth has been impacted by lower than expected vaccination rates, competitive pressures, and operational challenges in international markets.

Future Outlook

Moderna aims to secure up to 10 product approvals over the next three years and expects this to drive sales growth and fund the next wave of R&D investment.

Management Comments

• The Board has been actively involved in engaging with management on the lessons to be learned from this past season.
• We anticipate that in this role, Dr. Hoge will be in a position to align our R&D efforts with our Commercial organization as we seek to launch several new products over the next few years.

Industry Context

The document highlights the competitive landscape in the COVID and RSV vaccine markets, indicating a shift from a pandemic-driven business to a sustainable commercial model.

Comparison to Industry Standards

• The document mentions Moderna's 40% market share in the U.S. retail channel for its COVID vaccine, Spikevax (Source: IQVIA).
• The company compares its R&D success rate to the traditional biopharmaceutical industry, stating that it has been significantly higher.
• The document references a compensation peer group consisting of companies like Alnylam Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Amgen, Gilead Sciences, Regeneron Pharmaceuticals, BeiGene Ltd., Incyte Corporation, Vertex Pharmaceuticals, and BioMarin Pharmaceutical.

Management Changes

Corporate Governance

Stakeholder Impact

• The company's performance and strategic decisions impact shareholders, employees, customers, and the broader healthcare community.
• The company is committed to advancing representative diversity in clinical trials by identifying the barriers that currently impede inclusion, and implementing approaches to more efficiently identify, engage, recruit and retain study participants from diverse backgrounds and vulnerable populations.

Next Steps

• Drive sales of Spikevax and mRESVIA.
• Focus on delivering up to 10 product approvals over the next three years.
• Deliver cost efficiency across the business.

Key Dates